TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
Apellis Pharmaceuticals developed SYFOVRE™ (pegcetacoplan injection) for the treatment of secondary age-related macular degeneration (AMD). SYFOVRE™ (pegcetacoplan injection) is the only therapy approved for geographic atrophy (GA). By targeting C3, pegcetacoplan is designed to provide comprehensive control...
Abbisko Therapeutics discovered novel CSF-1R inhibitor Pimicotinib（ABSK021) for the treatment of tenosynovial giant cell tumour (TGCT) patients not responding to surgery. Pimicotinib is the first new generation CSF-1R drug candidate in the world. It is a novel, oral, highly selective and highly potent small molecule inhibitor of CSF-1R. Several studies have shown...
Loxo@Lilly the oncology unit of Eli Lilly and Company discovered novel Jaypirca™ (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). Jaypirca is the first and only BTK inhibitor specifically discovered for patients with mantle cell lymphoma...
Innovent Biologics, Inc. Discovered novel IBI351/GFH925(KRASG12C Inhibitor) as monotherapy for the patients previously treated with advanced non-small cell lung cancer. It is applicable for patients with KRASG12C mutation who have received at least one prior line of systemic therapy....
Akero Therapeutics, discovered novel Efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH). Efruxifermin (EFX) also known to be AKR-001, currently being evaluated in the ongoing Phase 2b HARMONY study is the main leading candidate for NASH...
IVERIC bio, Inc developed avacincaptad pegol to treat geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). Avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitorhave shown positive results from the 12-month pre-specified primary endpoint data in the GATHER1 and GATHER2 pivotal...
Pfizer Inc, developed investigational elranatamab a cancer immunotherapy for the treatment of indivuduals with relapsed or refractory multiple myeloma (RRMM). Elranatamab is bindedwith B-cell maturation antigen (BCMA)-CD3-targeted bispecific antibody (BsAb), present on the surface of multiple myeloma (MM) cells, and the CD3 receptor found...
Rhythm Pharmaceuticals, Inc discovers first-of-its-kind setmelanotide for the treatment of obesity. Setmelanotide is not indicated for treating patients with suspected obesity due to POMC, PCSK1 or LEPR deficiency with POMC, PCSK1 or LEPR variants classified as benign or likely benign. It is also not indicated for obesity related...
Akeso Biopharma developed novel Ivonescimab (PD-1/VEGF bispecific antibody in combination with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma (NSCLC) patients. Novel Ivonescimab is applicable for patients who have failed to respond to prior PD-(L)1...
Connoya introduced CMG901, novel drug for the treatment of Claudin 18.2-positive advanced gastric cancer. This new drug is indicated after first-line or treatment failure or intolerance. CMG901 previously granted orphan drug designation and fast track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory gastric cancer...
